Paul Zolkind

Assistant Professor

Washington University in St. Louis

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Paul Zolkind is an Assistant Professor at Washington University in St. Louis, USA. His research areas primarily focus on cancer immunobiology, specifically the role of NRF2 in cancer and its implications for immunotherapy. He is also engaged in studying HPV-related survival disparities in oropharyngeal cancer and the impact of socioeconomic status on treatment outcomes. Additionally, his work includes exploring innovative approaches in head and neck cancer treatment and understanding factors influencing the natural history of untreated head and neck cancer.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

UNITED STATES

View details

ravindra uppaluri

Division Chief

Brigham and Women's Hospital

UNITED STATES

View details

Sidharth V. Puram

Washington University School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Paul Zolkind

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

NRF2 immunobiology in cancer: implications for immunotherapy and therapeutic targeting

Patient‐Reported Swallowing Outcomes in HPV+ Oropharyngeal Cancer by Postoperative Chemoradiation Dose in MINT and E3311

NRF2 Activation in Trp53;p16-deficient Mice Drives Oral Squamous Cell Carcinoma

Race and socioeconomic status interact with HPV to influence survival disparities in oropharyngeal squamous cell carcinoma

Integrating CD4 + T cell help for therapeutic cancer vaccination in a preclinical head and neck cancer model

Untreated head and neck cancer: Natural history and associated factors

Erratum: Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus⇓unrelated head and neck cancer: A multicenter, phase II trial (CLINICAL CANCER RESEARCH2020;26:5140–52 DOI: 10.1158/1078-0432.CCR-20-1695)

Yap1 mediates trametinib resistance in head and neck squamous cell carcinomas

Negative-Pressure Aerosol Cover for COVID-19 Tracheostomy

Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor antigen–specific T cells

Collaborators (7)

Angela Mazul

Samera Hamad

Michael Major

Sean Massa

Rani Sellers

ravindra uppaluri

Sidharth V. Puram

Make your next move.